Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 18Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 4Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Salivary Gland Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Urothelial Cancer 1Meningeal Carcinomatosis 1Lung Diseases 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Cisplatin 22pembrolizumab 21Carboplatin 12Radiotherapy 11Paclitaxel 11Brachytherapy 11Drug Therapy 10Bevacizumab 9Blood Specimen Collection 7Colposcopy 6Specimen Handling 5Injections 5toripalimab 4Taxes 4Surveys and Questionnaires 4Nivolumab 4Mass Screening 4Human Papillomavirus DNA Tests 4Gemcitabine 4Chemotherapy, Adjuvant 4Chemoradiotherapy 4spartalizumab 3lenvatinib 3camrelizumab 3aldesleukin 3Restraint, Physical 3Radiation 3Fulvestrant 3Cyclophosphamide 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Cervical Neoplasms × sacituzumab govitecan × Clear all
NCT05838521 2026-02-06

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Yale University

Phase 2 Recruiting
20 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡